Odyssey Health, INC 8-K filings

Odyssey Health's agreement to distribute Davion Healthcare's BreastCheck product has been cancelled due to NeuRX Health's failure to secure necessary approvals.

Odyssey Health has finalized an agreement to acquire exclusive worldwide marketing and distribution rights for the BreastCheck non-invasive screening device.

Odyssey Health, Inc. has secured extensions for multiple promissory notes, pushing repayment deadlines into 2026 and 2027.

Odyssey Health, Inc. announced a multi-million-dollar, nine-year maintenance service contract and a financing facility of up to $25 million to support strategic growth and commercialization initiatives.

Odyssey Health, Inc. has acquired exclusive worldwide sub-licensing rights to BreastCheck, a non-invasive breast abnormality test, aiming to enter the growing breast cancer diagnostics market.

Odyssey Health, Inc. has extended the maturity date of its $870,000 promissory note with Mast Hill Fund, L.P. to April 30, 2026, and eliminated amortization payments.

Odyssey Health, Inc. has secured a $100,000 promissory note with an 18% interest rate and issued 100,000 common stock warrants to a private investor.

Odyssey Health, Inc. has extended the maturity date of a $1.05 million convertible promissory note with LGH Investments, LLC to January 31, 2026.

Odyssey Health, Inc. has entered into a securities purchase agreement with Mast Hill Fund, L.P. for a $220,000 promissory note and warrants, yielding $173,000 in net proceeds for business development and working capital.

Odyssey Health, Inc. has extended the maturity date of a $300,000 promissory note with Peter J. DArruda to January 31, 2026.

Odyssey Health, Inc. announced an extension of the maturity date for a convertible promissory note with investor Jonathan Lutz to January 31, 2026.

Odyssey Health, Inc. entered into a $25 million equity purchase agreement with Mast Hill Fund L.P. to bolster its financial position and fund operations.

Odyssey Health, Inc. has extended the maturity date of promissory notes held by two directors and two officers to January 31, 2026, marking the eleventh such amendment.

Odyssey Health, Inc. has extended the maturity date of its $870,000 promissory note with Mast Hill Fund, L.P. to October 10, 2025.

Odyssey Health, Inc. announced that FINRA has approved its name change on the OTC Markets, effective May 27, 2025, with the trading symbol ODYY remaining unchanged.

Odyssey Health, Inc. has extended the maturity dates of two promissory notes with Jon Lutz and LGH Investments, LLC to July 31, 2025.

Odyssey Health, Inc. has amended promissory notes with its directors and officers, extending the maturity date to July 31, 2025.

Odyssey Health, Inc. has entered into a promissory note agreement, securing $300,000 in funding with an 18% interest rate and issuing warrants for 300,000 shares of common stock.